Clinical Trials Logo

Drug Interaction Potentiation clinical trials

View clinical trials related to Drug Interaction Potentiation.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05558150 Completed - Clinical trials for Drug Interaction Potentiation

Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac

Start date: November 10, 2022
Phase: Phase 1
Study type: Interventional

This study evaluate the pharmacokinetic drug interactions and safety after co-administration of ilaprazole and Aceclofenac in healthy adults.

NCT ID: NCT05237297 Completed - Clinical trials for Drug Interaction Potentiation

Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole

Start date: February 17, 2022
Phase: Phase 1
Study type: Interventional

This study evaluate the pharmacokinetic drug interactions and safety after co-administration of ilaprazole and NSAID in healthy adults.

NCT ID: NCT03886701 Completed - Clinical trials for Human Immunodeficiency Virus

Doravirine, Rifapentine and Isoniazid Interaction

DORIIS
Start date: April 22, 2019
Phase: Phase 1
Study type: Interventional

Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex. Anti-tuberculosis drugs used to treat LTBI often induce drug metabolizing enzymes that share the same metabolic pathway as antiretroviral drugs used for those living with HIV/AIDS. This study evaluates the drug-drug interaction (DDI) potential of an antiretroviral drug when co-administered with a common anti-tuberculosis regimen of drugs.

NCT ID: NCT03801759 Completed - Clinical trials for Drug Interaction Potentiation

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

Start date: July 20, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, 3-arm, fixed sequence, study to evaluate vadadustat as a perpetrator of drug-drug interactions (DDIs) with digoxin, adefovir and furosemide in healthy male and female subjects.

NCT ID: NCT03801746 Completed - Clinical trials for Drug Interaction Potentiation

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

Start date: July 20, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, two-part, open-label study to evaluate the interaction of cyclosporine, probenecid, and rifampin as perpetrators with vadadustat (victim) in healthy male and female subjects.

NCT ID: NCT03801733 Completed - Clinical trials for Drug Interaction Potentiation

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

Start date: June 17, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, three-part, open-label study to evaluate vadadustat as a perpetrator in drug-drug interactions with rosuvastatin, sulfasalazine, pravastatin, atorvastatin and simvastatin in healthy male and female subjects.

NCT ID: NCT03789032 Completed - Pharmacokinetics Clinical Trials

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Start date: October 3, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, fixed sequence, open-label study to evaluate the effect of multiple oral doses of rabeprazole on the pharmacokinetics of a single dose of vadadustat 300 mg in healthy male and female subjects.

NCT ID: NCT03706222 Completed - Clinical trials for Drug Interaction Potentiation

Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

Start date: October 22, 2018
Phase:
Study type: Observational

Co-morbid diseases often present in a substantial proportion of patients with chronic hepatitis C (CHC) and require drugs to treat and control. Grazoprevir/elbavir is metabolized by cytochrome P-450 enzyme of liver. Drug-drug interactions (DDIs) are important issue before commencing direct acting antiviral agents (DAA) treatment for CHC patients. Few studies from Western countries reported that the percentages of DDIs of grazoprevir/elbasvir are limited.In Asia, real-world analysis of DDIs of grazoprevir/elbasvir is lacking and needs to be clarified.

NCT ID: NCT03493698 Completed - Clinical trials for Drug Interaction Potentiation

A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects

Start date: May 7, 2018
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, fixed sequence study to investigate the effect of multiple oral dosing of Inarigivir Soproxil and a single oral dose of Midazolam in Healthy Subjects

NCT ID: NCT03259542 Completed - Healthy Clinical Trials

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

Start date: August 9, 2017
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-center, fixed-sequence, open label, drug-drug interaction study of the effect of multiple daily doses of oral itraconazole 200 mg, a strong inhibitor of CYP3A, given with mifepristone 900 mg QD, in healthy male subjects, where all drug administrations are given after a meal.